$CLLS

Cellectis SA (CLLS) shares dropped 14.6% after Barclays downgraded the stock to Underweight, cutting its price target to $1.30 from $9.00. Analyst Lukas Shumway cited lack of conviction in Cellectis' new programs, assigning negative net present values to .HEAL-101 and .HEAL-201. The valuation model now includes $2 each for Royalties and Milestones, -$1 for Debt, and $5 for Cash, assuming a capital raise in late 2027.

Analysts made several rating changes: Wolfe upgraded Paychex (PAYX) citing stable employment trends. UBS upgraded Union Pacific (UNP) to Buy with a $339 price target, expecting strong 2027 volume growth. Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target after FDA reaffirmed study design. JPMorgan upgraded Credicorp (BAP) to Overweight with a $482 target, seeing strong EPS growth. Morgan Stanley downgraded Expedia (EXPE) to Underweight with a $235 target, citing weaker assets

Analysts downgraded several stocks: HSBC cut Banco Santander Brasil (BSBR) to Hold with a $6.2 target; Rosenblatt downgraded Ribbon Communications (RBBN) to Neutral with a $2.2 target; Citizens downgraded Cellectis (CLLS) to Market Perform; Barclays downgraded Scholar Rock (SRRK) to Equal-Weight with a $58 target; Raymond James downgraded Ascendis Pharma (ASND) to Outperform with a $287 target.

Cellectis (CLLS) reported Q2 2026 cash, cash equivalents and fixed-term deposits of $169M as of June 30, 2026, versus $145M in Q2 2025, citing runway into Q4 2027. At EHA 2026, lasme-cel in BALLI-01 moved to pivotal Phase 2 after FDA RMAT (June 2026), with ORR 67% and CR 56% in Phase 1. Eti-cel in NATHALI-01 showed ORR 46% and CR 31%.

Cellectis held its general shareholders meeting in Paris on June 25, 2026, with about 55.84% of voting rights represented. According to the company, resolutions 1–29 were adopted and resolution 30 was rejected, in line with the board’s recommendations. Voting results and resolution details are posted on Cellectis’ website.

Cellectis said the FDA granted RMAT designation to lasme-cel, its CD22-targeting allogeneic CAR-T candidate, for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The company cited Phase 1 BALLI-01 data for efficacy and a manageable safety profile. Final Phase 1 results are scheduled for presentation at EHA on June 13; BALLI-01 Phase 2 enrollment is open.

Cellectis S.A., a clinical-stage biotechnology company, announced that its annual general meeting of shareholders will take place on June 25, 2026, at the Biopark auditorium in Paris at 2:30 p.m. CET. The company, which specializes in gene-edited CAR T-cell therapies, provides details and materials for the meeting on its website. TipRanks' AI Analyst, Spark, rates CLLS as Neutral due to weak financial performance marked by ongoing losses and rising leverage, despite moderately supportive technical indicators.

Cellectis S.A., a clinical-stage biotechnology company, announced it will release its first-quarter 2026 financial results on May 11, 2026, after the U.S. market close. The company will issue a press release on its website but will not host a conference call, directing investors to its investor relations team for inquiries. Currently, analyst ratings for CLLS stock lean towards a "Buy" with a $9.00 price target, while TipRanks' AI Analyst, Spark, rates it as "Neutral" due to financial performance concerns.

Cellectis has unveiled a significant advancement in genetic medicine with its new platform that can turn off disease-related genes without altering the DNA sequence. This epigenetic editing approach uses TALE-based epigenetic modulators (TALEM) to modify gene expression, offering a potentially safer and reversible alternative to traditional gene editing like CRISPR-Cas9. The company demonstrated over 90% reduction in target gene activity in hepatocytes and T-cells, with stable epigenetic modifications, positioning it as a key player in the rapidly growing epigenetics market.

Cellectis announced positive interim futility analysis data from Allogene’s pivotal ALPHA3 trial for cema-cel in large B-cell lymphoma, showing 58.3% MRD negativity compared to 16.7% for observation. The treatment demonstrated favorable tolerability with most patients managed as outpatient, and Cellectis is eligible for up to $340 million in milestones and royalties. However, full trial accrual and primary event-free survival analysis are not expected until mid-2028, extending the regulatory timeline.